CSIMarket
 


Replimune Group Inc   (REPL)
Other Ticker:  
 


Replimune Group Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Replimune Group Inc 's ROA in the third quarter of 2024?
Replimune Group Inc recorded a cumulative net loss of $-210 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -35.81%.

However, within the Healthcare sector 296 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2023 quarter, so far to 2649, from total ROA ranking in the second quarter of 2024 at 3809.

What is ROA?


Return On Assets (Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Total Assets Change -21.5 % 28.96 % 31.39 % 40.2 % 39.83 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -210 -199 -182 -174 -157
Return On Assets (TTM) -35.81 % -31.88 % -30.71 % -31.39 % -30.81 %
REPL's Total Ranking # 2649 # 3809 # 3980 # 4090 # 4615
Total Assets (TTM) in million 533 562 604 647 679
Seq. Total Assets Change -5.29 % -6.83 % -6.64 % -4.71 % 55.6 %
Seq. Net Income Change - - - - -



Return On Assets Company Ranking
Within: No.
Industry # 38
Sector # 297
Overall # 2639

Return On Assets Statistics
High Average Low
-7.25 %
-23.12 %
-35.8 %
(Jun 30 2020)   (Dec 31 2023)



  News about Replimune Group Inc

Replimune Appoints New CEO and Strengthens Executive Team as Shares Surge

Replimune Announces Leadership Transitions and Strengthened Executive Team as Shares Trade Higher
Replimune Group Inc, a renowned biotechnology company specializing in oncolytic immunotherapies, has recently announced significant leadership transitions and the appointment of Sushil Patel as CEO. The company's former CEO, Philip Astley-Sparke, will now assume the role of Executive Chairman. This move aims to enhance Replimune's growth strategy and support its mission to revolutionize cancer treatment.
In addition to the management shakeup, Replimune also revealed its financial performance for the past year. The company recorded a cumulative net loss of $-210 million during the twelve months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -35.81%. However, despite the financial challenges, Replimune's return on assets has improved significantly, moving up to 2554 from its previous ranking at 3809 in the second quarter of 2024.
Replimune operates within the highly competitive Healthcare sector, where 286 other companies boast higher return on assets. Nevertheless, the company's recent advancements indicate positive strides towards achieving its financial goals and solidifying its position in the industry.




Financial Statements
Replimune Group Inc 's Assets $ 533 million REPL's Balance sheet
Replimune Group Inc 's Income $ -51 million Quarterly REPL's Income Statement
REPL's Income by Division See REPL's Income by Division



Annual Return On Assets (Mar 31 2023)
FY 2023
(Mar 31 2022)
FY 2022
(Mar 31 2021)
FY 2021
(Mar 31 2020)
FY 2019

FY
Y / Y Total Assets Change 40.2 % -15.08 % 132 % - -
Total Assets in million 647 461 543 234 0
Y / Y Net Income Change - - - - -
Net Income in million -174 -118 -81 -53 0
Return On Assets -26.95 % -25.59 % -14.89 % -22.48 % -




More Return On Assets Ratios
REPL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
REPL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Roa for REPL's Competitors
Roa for Replimune Group Inc 's Suppliers
Return On Assets for REPL's Customers

You may also want to know
REPL's Roi REPL's Inventory Turnover Ratio REPL's Growth Rates REPL's Dividend Comparisons
REPL's Profitability Ratios REPL's Asset Turnover Ratio REPL's Dividend Growth
REPL's Roe REPL's Valuation Ratios REPL's Financial Strength Ratios REPL's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector ROA


Date modified: 2024-02-08T15:37:20+00:00


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com